What the Evidence Actually Shows About Medical Marijuana for Cancer
A review of cannabinoid pharmaceuticals found the strongest evidence supports their use for chemotherapy-induced nausea and AIDS-related appetite loss, with more limited data for cancer pain.
Quick Facts
What This Study Found
This clinical review examined evidence for three cannabinoid pharmaceuticals: dronabinol (synthetic THC), nabilone (THC analog), and nabiximols (THC/CBD spray), along with smoked marijuana.
Dronabinol had the most established evidence base, with FDA approval for chemotherapy nausea and AIDS-related anorexia. Nabilone was also well-studied for chemotherapy nausea. Nabiximols, available only through U.S. clinical trials at the time, was used in Canada and the UK for multiple sclerosis spasticity and pain.
For cancer-specific applications, evidence centered on nausea management, appetite stimulation, and pain relief, though the pain data was more limited. The review also documented adverse effects including dizziness, euphoria, sedation, and cognitive impairment.
Key Numbers
Three FDA-related cannabinoid drugs reviewed; dronabinol FDA-approved for two indications; nabiximols available in U.S. only through clinical trials
How They Did This
Narrative review of published clinical literature on medical marijuana and cannabinoid pharmaceuticals, with emphasis on oncology-relevant indications. Published in a major oncology journal (CA: A Cancer Journal for Clinicians).
Why This Research Matters
This review from a leading oncology journal provided clinicians with an evidence-based perspective on cannabinoid use in cancer care, cutting through both the hype and stigma to identify where data actually supported benefit.
The Bigger Picture
The gap between public enthusiasm for medical marijuana in cancer and the actual clinical evidence remains significant. Established cannabinoid pharmaceuticals have clearer evidence profiles than whole-plant cannabis for specific symptoms.
What This Study Doesn't Tell Us
Narrative review without systematic search methodology. Many reviewed studies predated modern cannabis products and potencies. Did not compare cannabinoids head-to-head with newer anti-nausea medications.
Questions This Raises
- ?How do cannabinoids compare to newer antiemetic drugs for chemotherapy nausea?
- ?Would whole-plant cannabis products offer advantages over isolated cannabinoid pharmaceuticals?
- ?What is the optimal role of cannabinoids in comprehensive cancer symptom management?
Trust & Context
- Key Stat:
- Strongest evidence: chemotherapy nausea and AIDS-related appetite loss
- Evidence Grade:
- Published in a top-tier oncology journal reviewing multiple levels of evidence, though it is a narrative review rather than a systematic analysis.
- Study Age:
- Published in 2015. The landscape of both cannabinoid research and anti-nausea medications has evolved considerably.
- Original Title:
- Medical marijuana for cancer.
- Published In:
- CA: a cancer journal for clinicians, 65(2), 109-22 (2015)
- Authors:
- Kramer, Joan L
- Database ID:
- RTHC-00996
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical marijuana proven to help with cancer?
The strongest evidence supports specific cannabinoid pharmaceuticals for chemotherapy-induced nausea and appetite loss. Evidence for pain relief is more limited, and no evidence shows cannabinoids treat cancer itself.
What are the side effects of cannabinoid medications?
Documented adverse effects include dizziness, euphoria, sedation, confusion, and cognitive impairment. These effects vary by dose and individual tolerance.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00996APA
Kramer, Joan L. (2015). Medical marijuana for cancer.. CA: a cancer journal for clinicians, 65(2), 109-22. https://doi.org/10.3322/caac.21260
MLA
Kramer, Joan L. "Medical marijuana for cancer.." CA: a cancer journal for clinicians, 2015. https://doi.org/10.3322/caac.21260
RethinkTHC
RethinkTHC Research Database. "Medical marijuana for cancer." RTHC-00996. Retrieved from https://rethinkthc.com/research/kramer-2015-medical-marijuana-for-cancer
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.